Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fluvoxamine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dosing Period 1 | EXPERIMENTAL | - |
| Dosing Period 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Fluvoxamine | DRUG | Multiple doses of fluvoxamine |
| RO4917523 | DRUG | Single dose of RO4917523 |
Inclusion Criteria: * Healthy volunteers, 18-65 years of age inclusive * Non-smokers * Body mass index (BMI) between 18 and 30 mg/m2 inclusive * Women who are not menopausal or surgically sterile agree to use two adequate methods of contraception Exclusion Criteria: * Evidence of any active or ch...
Fluvoxamine is a small molecule being studied in a Phase 1 clinical trial in healthy volunteers. The trial is designed to evaluate the effect of Fluvoxamine on the pharmacokinetics of another drug, RO4917523. It is not approved for any indication and remains investigational.
Fluvoxamine is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research on this small molecule drug in healthy volunteer studies.
Fluvoxamine is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The current Phase 1 trial is completed, and no active trials are ongoing.
Fluvoxamine has one completed Phase 1 clinical trial, identified as NCT01665404. This study, conducted in France, enrolled 16 healthy volunteers aged 18 years and older to assess the effect of Fluvoxamine on the pharmacokinetics of RO4917523.
Fluvoxamine is not FDA approved for the indication being studied. It is an investigational drug currently in Phase 1 clinical development. The completed trial focused on healthy volunteers and did not involve a patient population.